metricas
covid
Buscar en
Enfermedades Infecciosas y Microbiología Clínica
Toda la web
Inicio Enfermedades Infecciosas y Microbiología Clínica Relación entre detección de anticuerpos anti-CagA, sensibilidad antibiótica y...
Journal Information
Vol. 21. Issue 3.
Pages 137-141 (March 2003)
Share
Share
Download PDF
More article options
Vol. 21. Issue 3.
Pages 137-141 (March 2003)
Full text access
Relación entre detección de anticuerpos anti-CagA, sensibilidad antibiótica y úlcera péptica en pacientes con infección por Helicobacter pylori
Association among anti-CagA antibody detection, antibiotic susceptibility, and peptic ulcer in patients with Helicobacter pylori infection
Visits
5818
Carlos Toroa,1
Corresponding author
carlostororueda@hotmail.com

Correspondencia: Dr. C. Toro. Servicio de Enfermedades Infecciosas. Hospital Carlos III. Sinesio Delgado, 10. 28029 Madrid. España
, Javier García-Samaniegob, Teresa Alarcónc, Margarita Baquerod
a Servicio de Enfermedades Infecciosas. Hospital Carlos III
b Servicio de Digestivo. Hospital Carlos III
c Servicio de Microbiología. Hospital de la Princesa
d Servicio de Microbiología. Hospital Carlos III. Madrid. España
This item has received
Article information
Introducción

El propósito de este estudio fue determinar si la presencia de anticuerpos frente a las proteínas de virulencia CagA y VacA de Helicobacter pylori se asociaba con una mayor sensibilidad a los antibióticos, y su relevancia clínica en los pacientes con dispepsia.

Métodos

Se estudiaron 98 pacientes adultos con infección por H. pylori que acudieron a realizarse una endoscopia gástrica por sus síntomas dispépticos. La determinación de anticuerpos anti-CagA y anti-VacA se realizó mediante Western-blot (Helicoblot 2.0). Se estudió la concentración mínima inhibitoria a amoxicilina, metronidazol, claritromicina y tetraciclina mediante E-test.

Resultados

Fueron diagnosticados de dispepsia ulcerosa 39 pacientes y 59 de dispepsia no ulcerosa. Presentaron anticuerpos anti-CagA 63 pacientes y 52 anti-VacA que en ambos casos se asociaron significativamente con la presencia de dispepsia ulcerosa (p = 0,034 y p = 0,029, respectivamente). Se detectaron un 38,8% de cepas resistentes a metronidazol y un 10,3% a claritromicina. No se observaron resistencias a amoxicilina ni a tetraciclina. La sensibilidad a claritromicina fue más frecuente en pacientes con dispepsia ulcerosa frente a los sujetos con dispepsia no ulcerosa (p = 0,046). Los pacientes con anticuerpos anti-CagA presentaron las cepas más sensibles a los antibióticos, siendo para la claritromicina la diferencia estadísticamente significativa (p < 0,001).

Conclusió

La detección de anticuerpos anti-CagA se asoció con una mayor sensibilidad a los antibióticos en pacientes con dispepsia ulcerosa y no ulcerosa, por lo que su detección podría ser un marcador de buen pronóstico de éxito terapéutico.

Palabras clave:
Helicobacter pylori
Resistencia
CagA
VacA
Claritromicina
Introduction

The aim of this study was to determine the relationship among antibodies against virulence factors (CagA and VacA), clinical status and primary resistance in dyspeptic patients with Helicobacter pylori infection.

Methods

Ninety-eight adult patients with Helicobacter pylori infection who underwent gastric endoscopy for dyspepsia were studied. Specific serum IgG antibodies against CagA and VacA proteins were detected by Western-blot (Helicoblot 2.0). Minimum inhibitory concentrations of metronidazole, amoxicillin, tetracycline and clarithromycin were determined with the E-test.

Results

Thirty-nine patients presented peptic ulcer disease and 59 had non-ulcer dyspepsia. CagA protein was detected in 63 patients, and VacA protein in 52 subjects, and both were significantly associated with peptic ulcers (p = 0.034 and p = 0.029, respectively). Susceptibility results showed 38.8% of strains resistant to metronidazole and 10.3% resistant to clarithromycin. No resistance to amoxicillin or tetracycline was found. Susceptibility to clarithromycin was more frequent in ulcer patients than in non-ulcer dyspepsia patients (p = 0.046). CagA protein was more frequent in patients with clarithromycin-sensitive strains (p < 0.001).

Conclusion

Antibodies against CagA protein were associated with higher antibiotic susceptibility in patients with ulcers or non-ulcer dyspepsia. Thus, anti-CagA antibody detection could be a useful marker of favorable prognosis with antibiotic treatment.

Key words:
Helicobacter pylori
Resistance
CagA
VacA
Clarithromycin
Full text is only aviable in PDF
Bibliografía
[1.]
D.Y. Graham, H.M. Malaty, D.G. Evans, D.J. Jr. Evans, P.D. Klein, E. Adam.
Epidemiology of Helicobacter pylori in asymptomatic population in the United States. Effect of age, race, and socioeconomic status.
Gastroenterology, 100 (1991), pp. 1495-1501
[2.]
E.J. Kuipers, J.C. Thijs, H.P. Festen.
The prevalence of Helicobacter pylori in peptic ulcer disease.
Aliment Pharmacol Ther, 9 (1995), pp. 59-69
[3.]
C. Boixeda, J.P. Gisbert, R. Cantón, I. Álvarez Baleriola, F. Bermejo, R. Aller.
Helicobacter pylori, úlcera gástrica y antiinflamatorios no esteroideos.
Med Clin (Barc), 106 (1996), pp. 209-212
[4.]
J. Parsonnet, S. Hansen, L. Rodríguez, A.B. Gelb, R.A. Warnke, E. Jellum.
Helicobacter pylori infection and gastric MALT lymphoma.
N Engl J Med, 330 (1994), pp. 1267-1271
[5.]
N. Uemura, S. Okamoto, S. Yamamoto, N. Matsumura, S. Yamaguchi, M. Yamakido.
Helicobacter pylori infection and the development of gastric cancer.
N Engl J Med, 345 (2001), pp. 784-789
[6.]
J.E. Crabtree, J.D. Taylor, J.I. Wyatt, R.V. Heatley, T.M. Shallcross, D.S. Tompkins.
Mucosal IgA recognition of Helicobacter pylori 120 kDa protein, peptic ulceration and gastric pathology.
Lancet, 338 (1991), pp. 332-335
[7.]
M.J. Blaser, G.I. Pérez-Pérez, H. Kleanthous, R.M. Peek, P.H. Chyou, G.N. Stemmermann.
Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach.
Cancer Res, 55 (1995), pp. 2111-2115
[8.]
M.J. Blaser.
Heterogeneity of Helicobacter pylori.
Eur J Gastroenterol Hepatol, 9 (1997), pp. 3-6
[9.]
D. Domingo, T. Alarcón, N. Prieto, M. López-Brea.
Relación entre sensibilidad antibiótica y factores de virulencia en aislamientos clínicos de Helicobacter pylori.
Rev Esp Quimioterap, 12 (1999), pp. 340-345
[10.]
L.J. Van Doorn, P.M. Schneeberger, N. Nouhan, A.P. Plaisier, W.G.V. Quint, W.A. De Boer.
Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment.
Gut, 46 (2000), pp. 321-326
[11.]
N. Broutet, A. Marais, H. Lamouliatte, A. De Mascarel, R. Samoyeau, R. Salamon.
cagA status and eradication treatment outcome of anti-Helicobacter pylori triple therapies in patients with nonulcer dyspepsia.
J Clin Microbiol, 39 (2001), pp. 1319-1322
[12.]
T.L. Cover, Y. Glupczynski, A.P. Lage, A. Burette, M.K. Tummuru, G.I. Pérez-Pérez.
Serologic detection of infection with cagA+ Helicobacter pylori strains.
J Clin Microbiol, 33 (1995), pp. 1496-1500
[13.]
O.A. Paoluzi, P. Rossi, C. Montesano, S. Bernardi, E. Carnieri, O.P. Marchione.
Discrepancy between polymerase chain reaction assay and western blot analysis in the assessment of CagA status in dyspeptic patients.
Helicobacter, 6 (2001), pp. 130-135
[14.]
C. Figueiredo, W. Quint, N. Nouhan, H. Van der Munckhof, P. Herbrink, J. Scherpenisse.
Assessment of Helicobacter pylori vacA and cagA genotypes and host serological response.
J Clin Microbiol, 39 (2001), pp. 1399-1444
[15.]
Z. Maratka.
Gastroscopia.
Española, (1986),
[16.]
R. Cheli, A. Giacosa, E. Bovero.
Clinical significance of duodenal erosions.
Endoscopy, 16 (1984), pp. 105-108
[17.]
National Committee for Clinical Laboratory Standards.
Performance standards for antimicrobial susceptibility testing.
Eleventh informational supplement (aerobic dilution). NCCLS document M100-S11, 21 (2001),
[18.]
T. Lind, F. Mégraud, P. Unge, E. Bayerdorffer, C. O’Morain, R. Spiller.
The MACH2 study: Role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies.
Gastroenterology, 116 (1999), pp. 248-253
[19.]
F. Megraud, N. Lehn, T. Lind, E. Bayerdorffer, C. O’Morain, R. Spiller.
Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: The MACH2 study.
Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: The MACH2 study, 43 (1999), pp. 2747-2752
[20.]
Y. Glupczynski, M. Labbe, W. Hansen, F. Crokaert, E. Yourassowsky.
Evaluation of the E-test for quantitative antimicrobial susceptibility testing of Helicobacter pylori.
J Clin Microbiol, 29 (1991), pp. 2072-2075
[21.]
T. Alarcón, D. Domingo, M. López-Brea.
Antibiotic resistance problems with Helicobacter pylori.
Int J Antimicrob Agents, 12 (1999), pp. 19-26
[22.]
B. Grignon, J. Tankovic, F. Mégraud, Y. Glupczynski, M.O. Husson, M.C. Conroy.
Validation of diffusion methods for macrolide susceptibility testing of Helicobacter pylori.
Microb Drug Resist, 8 (2002), pp. 61-66
[23.]
R. Krausse, L. Garten, T. Harder, U. Ullmann, T. Birkner, M. Doniec.
Clinical relevance of CagA-specific antibodies related to CagA status of Helicobacter pylori isolates using immunofluorescence test and PCR.
Infection, 29 (2001), pp. 154-158
[24.]
Y. Yamaoka, T. Kodama, D. Graham, K. Kashima.
Comparison of four serological test to determine the CagA or VacA status of Helicobacter pylori strains.
J Clin Microbiol, 36 (1998), pp. 3433-3434
[25.]
S. Miehlke, M.F. Go, J.G. Kim, D.Y. Graham, N. Figura.
Serologic detection of Helicobacter pylori infection with cagA-positive strains in duodenal ulcer, gastric cancer, and asymptomatic gastritis.
J Gastroenterol, 33 (1998), pp. 18-21
[26.]
C.A. Rota, J.C. Pereira-Lima, C. Blaya, N.B. Nardi.
Consensus and variable region PCR analysis of Helicobacter pylori 3’ region of cagA gene in isolates from individuals with or without peptic ulcer.
J Clin Microbiol, 39 (2001), pp. 606-612
[27.]
N.S. Taylor, J.G. Fox, N.S. Akopyants, D.E. Berg, N. Thompson, B. Shames.
Long-term colonization with single and multiple strains of Helicobacter pylori assessed by DNA fingerprinting.
J Clin Microbiol, 33 (1995), pp. 918-923
[28.]
A. Van der Ende, E.A.J. Raws, M. Feller, C.J. Mulder, G.N. Tytgat, J. Dankert.
Heterogeneous Helicobacter pylori isolates from members of a family with a history a peptic ulcer disease.
Gastroenterology, 111 (1996), pp. 638-647
[29.]
N. Figura, C. Vindigni, A. Covacci, L. Presenti, D. Burroni, R. Vernillo.
CagA positive and negative Helicobacter pylori strains are simultaneously present in the stomach of most patients with non-ulcer dyspepsia: relevance of histological damage.
Gut, 42 (1998), pp. 772-778
[30.]
G.I. Pérez-Pérez, R.M. Peek, J.C. Atherton, M.J. Blaser, T.L. Cover.
Detection of anti-VacA antibody responses in serum and gastric juice samples using type s1/m1 and s2/m2 Helicobacter pylori VacA antigens.
Clin Diagn Lab Immunol, 6 (1999), pp. 489-493
[31.]
S. Censini, C. Lange, Z. Xiang, J.E. Crabtree, P. Ghiara, M. Borodovsky.
CAG, a pathogenicty island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors.
Proc Natl Acad Sci, 93 (1996), pp. 14648-14653
Copyright © 2003. Elsevier Ltd. Todos los derechos reservados
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos